Anti-SARS-CoV-2 (Coronavirus), IgM
Anti-SARS-CoV-2 (Coronavirus) antibodies test are done to detect the IgA, IgG and IgM antibodies formed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 was previously named 2019 novel coronavirus or 2019-nCoV and informally known as the Wuhan coronavirus.
SARS-CoV-2 is the seventh known coronavirus causing respiratory infection in humans, after 229E, NL63, OC43, HKU1, MERS-CoV, and the original SARS-CoV. Based on its genome sequence, SARS-CoV-2 is a positive-sense, single-stranded RNA coronavirus (+ssRNA) belongs to the 2B group of the betacoronavirus family, which is the same family as SARS-CoV and MERS-CoV and has 70% similarity in genetic sequence to SARS. Each SARS-CoV-2 virion is approximately 50–200 nanometers in diameter and composed of several proteins including the spike (S), envelope (E), membrane (M), and nucleocapsid (N); the N protein holds the RNA genome, and the S, E, and M proteins together create the viral envelope. Its spike protein has sufficient affinity to the angiotensin-converting enzyme 2 (ACE2) receptor to use it as a mechanism of cell entry.
SARS-CoV-2 is the causative agent of coronavirus disease 2019 (COVID-19). The World Health Organization (WHO) declared the 2019–20 coronavirus outbreaks a Public Health Emergency of International Concern (PHEIC) on 30 January 2020 and a pandemic on 11 March 2020. Symptoms of COVID-19 range from mild fever, cough, and shortness of breath, muscle pain, diarrhea, and sore throat to pneumonia and multi-organ failure. The disease is transmitted from human-to-human by close contact, via respiratory droplets generated by sneezing and coughing. It may also spread when one touches a contaminated surface and then their face. The incubation period appears to be 2-14 days. The laboratory testing for the COVID-19 and the associated SARS-CoV-2 virus includes methods that detect the presence of the viral nucleic acids, rapid tests to detect viral antigens and those that detect antibodies produced in response to infection.
Detection of antibodies against viral antigens (spike, envelope, membrane, and nucleocapsid) may indicate recent or past infection. IgM/IgA antibody against SARS- CoV-2 is increased after one week of COVID-19 infection while IgG antibody after two weeks. Although, real-time polymerase chain reaction (RT-PCR) tests to detect viral RNA is preferable and widely adopted test in COVID-19 testing, it has several limitations, including low rates of detection due to poor specimen collection, and availability. Therefore, the detection of antibodies against SAR-CoV-2 can be an alternative to aid the diagnosis of COVID-19 and can be supportive testing to nucleic acid testing. In addition, as the viral load gradually decrease with the increase of serum antibody levels, antibody testing can help to determine the immune status of infected patients.
- As an aid in diagnosis of acute respiratory distress syndrome and sever pneumonia caused by SARS-CoV-2 coronavirus
- Disease management
Negative (Non-reactive)
Whole blood, serum, plasma.
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Int J Occup Environ Med. 2020 Feb 5;11(2):65-71. [PMID: 32020915]
- Lancet Infect Dis. 2020 Mar 23. pii: S1473-3099(20)30196-1. [PMID: 32213337]
- Euro Surveill. 2020 Jan;25(3). doi: 10.2807/1560-7917. [PMID: 31992387]
- Int J Antimicrob Agents. 2020 Feb 17:105924. [PMID: 32081636]
- J Med Virol. 2020 Feb 13. doi: 10.1002/jmv.25709. [PMID: 32056249]
- Pediatr Infect Dis J. 2005 Nov;24 (11 Suppl). [PMID: 16378050]
- Euro Surveill. 2012 Sep 27;17(39). [PMID: 23041020]
- Antivir Ther. 2007;12(4 Pt B):651-8. [PMID: 17944272]